Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q3 EPS of ($0.54), $0.18 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $2.92 million versus the consensus estimate of $454.07 thousand.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.